Abstracts

LEVERAGING NEUTROPHILS TO CONTROL HIV VIA IGA

Neutrophils are the most abundant white blood cell and are rapid responders to infections. Neutrophils are also the most potent mediators of Fc-effector functions and in addition to phagocytosis, neutrophils degranulate and can kill through the formation of extracellular traps. However, little is known about the role of neutrophils in antiviral control of HIV. Thus,…

EFFECTIVENESS AND SAFETY OF LPV/R PELLETS-BASED ART IN CHILDREN: 48-WEEK ANALYSIS

A palatable, heat-stable, easy-to-administer pellets’ formulation of LPV/r has received tentative USFDA approval for use in infants and young children. However, there are few data on its effectiveness and safety in routine care. The LIVING study evaluates the effectiveness, safety, PK and acceptability of LPV/r pellets + ABC/3TC (or AZT/3TC) dispersible tablets, in HIV+ children…

SAFETY, PK, & EFFICACY OF FTC/TAF IN HIV-INFECTED ADOLESCENTS (12-18 YRS)

Fixed-dose combination emtricitabine (FTC)/tenofovir alafenamide (TAF) is approved for adolescents (US, EU) and a recommended first-line NRTI backbone for adolescents (US). Safety and efficacy of TAF in adolescents has been demonstrated in studies of elvitegravir/cobicistat/FTC/TAF, including favorable bone and renal safety. Safety, pharmacokinetics (PK), and efficacy of other FTC/TAF-containing regimens in adolescents have not been…

BICTEGRAVIR/FTC/TAF SINGLE-TABLET-REGIMEN IN ADOLESCENTS: WEEK 24 RESULTS

Bictegravir (BIC), a novel, unboosted integrase strand transfer inhibitor (INSTI) with a high genetic barrier to resistance, has been coformulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) into a once daily, single-tablet regimen (STR) of small tablet size that can be taken with/without food. We report pharmacokinetics (PK), safety and efficacy from a planned interim…

P1101: PHASEI/II STUDY OF RALTEGRAVIR CONTAINING REGIMEN IN HIV-TB COTREATED CHILDREN

Current antiretroviral (ARV) treatment options for children co-infected with TB and HIV-infection are limited. RIF induces UDP-glucuronosyltransferase activity accelerating the clearance of raltegravir (RAL). In adults, doubling the RAL dose partially overcame this PK interaction with no safety concerns. We sought to determine the optimal and safe dose of RAL when administered with RIF-containing anti-TB…